
    
      This is a Phase 1, open label, multicenter, dose-escalation study of safety,
      pharmacokinetics, and pharmacodynamics of Minnelide™

      Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21
      days followed by a 7-day rest period. One cycle will equal 28 days. Dose escalation will
      follow a modified Fibonacci design.
    
  